Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/24445 |
Resumo: | COVID-19 is an acute respiratory infection caused by the potentially severe, highly transmissible, globally distributed SARS-CoV-2 coronavirus. The search for drugs that have activity on SARS-CoV-2 is a constant challenge without precedent in the validation of effective drugs in the treatment of patients affected by COVID-19. Objective: This integrative review aimed to assess studies in the scientific literature, involving clinical trials that evaluate the efficacy of drugs already available on the market for probable use in the treatment of COVID-19. Methodology: The search was conducted from April 2020 to June 2021 in the PubMed, SciElo and Lilacs databases, using the Health Science Descriptors (DeCS) "COVID-19", "SARS-CoV-2", "Drugs", "Trials Clinicals", "Treatments". The criteria for inclusion of articles in the search were those with abstract and text available in full electronically, written in English, Portuguese, and Spanish, published from April 2020 to June 2021, in scientific journals, and that evaluated the efficacy of probable drugs in the treatment of COVID-19 and clinical trials in hospitalized patients with the disease. Articles that did not jointly address the topic of the study, duplicate articles in the databases, review articles, articles based on in vitro / in vivo animal trials, articles based on traditional medicine, editorial type studies and also the reflexive articles were excluded. Results: Of the 210 articles identified, 132 were excluded for not meeting the inclusion criteria, and 78 articles that aimed to study drug efficacy in international clinical trials were selected for this study. Of these, 67 were in PubMed, 6 in SciELO, and 5 in Lilacs. A total of 49 drugs were analyzed, classified into 22 pharmacological classes. The main classes of drugs in studies were: direct acting antivirals in monotherapy, 8 (16.32%); immunomodulators, 7 (14.28%); immunomodulators + associations, 2 (4.08%); and immunostimulants + associations, 2 (4.08%). Conclusion: The drugs and their associations under study did not show specific therapeutic efficacy for the treatment of COVID-19; however, clinical trials indicated improvement in patients' clinical symptoms and hospital length of stay. However, some drugs showed significant adverse reactions, directly interfering with patient safety. |
id |
UNIFEI_e7dfd275afdb00efa27c6913b6c9e4d0 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/24445 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19Estudio de fármacos seleccionados en ensayos clínicos en la terapia farmacológica de la COVID-19Estudo dos fármacos selecionados em ensaios clínicos na terapia farmacológica da COVID-19 COVID-19SARS-CoV-2MedicamentosEnsayos ClínicosTerapéutica.COVID-19SARS-CoV-2MedicamentosEnsaio ClínicoTerapêutica.COVID-19SARS-CoV-2DrugsTrials ClinicalsTherapeutics.COVID-19 is an acute respiratory infection caused by the potentially severe, highly transmissible, globally distributed SARS-CoV-2 coronavirus. The search for drugs that have activity on SARS-CoV-2 is a constant challenge without precedent in the validation of effective drugs in the treatment of patients affected by COVID-19. Objective: This integrative review aimed to assess studies in the scientific literature, involving clinical trials that evaluate the efficacy of drugs already available on the market for probable use in the treatment of COVID-19. Methodology: The search was conducted from April 2020 to June 2021 in the PubMed, SciElo and Lilacs databases, using the Health Science Descriptors (DeCS) "COVID-19", "SARS-CoV-2", "Drugs", "Trials Clinicals", "Treatments". The criteria for inclusion of articles in the search were those with abstract and text available in full electronically, written in English, Portuguese, and Spanish, published from April 2020 to June 2021, in scientific journals, and that evaluated the efficacy of probable drugs in the treatment of COVID-19 and clinical trials in hospitalized patients with the disease. Articles that did not jointly address the topic of the study, duplicate articles in the databases, review articles, articles based on in vitro / in vivo animal trials, articles based on traditional medicine, editorial type studies and also the reflexive articles were excluded. Results: Of the 210 articles identified, 132 were excluded for not meeting the inclusion criteria, and 78 articles that aimed to study drug efficacy in international clinical trials were selected for this study. Of these, 67 were in PubMed, 6 in SciELO, and 5 in Lilacs. A total of 49 drugs were analyzed, classified into 22 pharmacological classes. The main classes of drugs in studies were: direct acting antivirals in monotherapy, 8 (16.32%); immunomodulators, 7 (14.28%); immunomodulators + associations, 2 (4.08%); and immunostimulants + associations, 2 (4.08%). Conclusion: The drugs and their associations under study did not show specific therapeutic efficacy for the treatment of COVID-19; however, clinical trials indicated improvement in patients' clinical symptoms and hospital length of stay. However, some drugs showed significant adverse reactions, directly interfering with patient safety.La COVID-19 es una infección respiratoria aguda causada por el coronavirus SARS-CoV-2, potencialmente grave, altamente transmisible y de distribución mundial. La búsqueda de fármacos con actividad contra el SARS-CoV-2 es un reto sin precedentes y constante en la validación de fármacos eficaces para el tratamiento de pacientes con COVID-19. Objetivo: Esta revisión integradora tuvo como objetivo evaluar los estudios en la literatura científica, con ensayos clínicos que evalúan la eficacia de los medicamentos ya disponibles en el mercado para su probable uso en el tratamiento de la COVID-19. Metodología: La investigación se llevó a cabo en el período de abril de 2020 a junio de 2021 en las bases de datos PubMed, SciElo y Lilacs, utilizando los buscadores de ciencias de la salud (DeCS) "COVID-19", "SARS-CoV-2", "Medicamentos", "Ensayo Clínico", "Terapéutica". Los criterios de inclusión de los artículos en la búsqueda fueron aquellos con resumen y texto disponible en formato electrónico completo, escritos en inglés, portugués y español, publicados entre abril de 2020 y junio de 2021, en revistas científicas y que evaluaran la eficacia de probables fármacos en el tratamiento de la COVID-19 y ensayos clínicos en pacientes hospitalizados con la enfermedad. Se excluyeron los artículos que no abordaban conjuntamente el tema del estudio, los artículos duplicados en las bases de datos, los artículos de revisión, los artículos basados en ensayos animales in vitro / in vivo, los artículos basados en la medicina tradicional, los estudios de tipo editorial y también los artículos reflexivos. Resultados: De los 210 artículos identificados, se excluyeron 132 por no cumplir los criterios de inclusión, y se seleccionaron para este estudio 78 artículos que pretendían estudiar la eficacia de los medicamentos en ensayos clínicos internacionales. De ellos, 67 en la base de datos PubMed; 6 por SciELO; y, 5 en Lilacs. Se analizaron 49 medicamentos, clasificados en 22 clases farmacológicas. Las principales clases de medicamentos en los estudios fueron: antivirales de acción directa en monoterapia, 8 (16,32%); inmunomoduladores, 7 (14,28%); inmunomoduladores + asociaciones, 2 (4,08%); e, inmunoestimulantes + asociaciones, 2 (4,08%). Conclusión: Los fármacos y sus asociaciones en estudio no presentan una eficacia terapéutica específica para el tratamiento de la COVID-19; sin embargo, los ensayos clínicos indican una mejora de los síntomas clínicos de los pacientes y del tiempo de internamiento. Sin embargo, algunos medicamentos mostraron reacciones adversas significativas, interfiriendo directamente con la seguridad del paciente.A COVID-19 é uma infecção respiratória aguda causada pelo coronavírus SARS-CoV-2, potencialmente grave, de elevada transmissibilidade e de distribuição global. A busca por drogas que apresentam atividade sobre o SARS-CoV-2 é um desafio constante sem precedentes na validação de medicamentos eficazes no tratamento de pacientes acometidos pela COVID-19. Objetivo: Esta revisão integrativa teve como objetivo avaliar trabalhos na literatura científica, envolvendo ensaios clínicos que avaliam a eficácia de drogas já disponíveis no mercado para provável utilização no tratamento da COVID-19. Metodologia: A pesquisa foi realizada no período de abril de 2020 até junho de 2021 nas bases de dados PubMed, SciElo e Lilacs, utilizando os Descritores em Ciências da Saúde (DeCS) “COVID-19”, “SARS-CoV-2”, “Medicamentos”, “Ensaio Clínico”, “Terapêutica”. Os critérios para inclusão dos artigos na pesquisa foram os que apresentaram resumo e texto disponibilizados na íntegra eletronicamente, escritos em inglês, português e espanhol publicados no período de abril de 2020 a junho de 2021, em periódicos científicos e que avaliaram a eficácia de prováveis fármacos no tratamento da COVID-19 e ensaios clínicos em pacientes hospitalizados portadores da doença. Foram excluídos os artigos que não abordaram, em conjunto, o tema do estudo, artigos duplicados nas bases de dados, artigos de revisão, artigos baseados em ensaios in vitro / in vivo em animais, artigos baseados em medicina tradicional, estudos do tipo editorial e também os artigos reflexivos. Resultados: Dos 210 artigos identificados, 132 foram excluídos por não atenderem os critérios de inclusão, sendo selecionados para este estudo 78 artigos que objetivaram o estudo da eficácia de fármacos em ensaios clínicos internacionais. Destes, 67 estavam indexados na base de dados PubMed; 6 pelo SciELO; e, 5 na Lilacs. Foram analisados 49 fármacos, classificados em 22 classes farmacológicas. As principais classes de fármacos em estudos foram: antivirais de ação direta em monoterapia, 8 (16,32%); imunomoduladores, 7 (14,28%); imunomoduladores + associações, 2 (4,08%); e, imunoestimulantes + associações, 2 (4,08%). Conclusão: Os fármacos e suas associações em estudo não apresentaram eficácia terapêutica específica para o tratamento da COVID-19; porém, os ensaios clínicos indicaram melhora dos sintomas clínicos dos pacientes e do tempo de internamento hospitalar. Entretanto, alguns fármacos apresentaram significativas reações adversas, interferindo diretamente na segurança dos pacientes.Research, Society and Development2022-01-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2444510.33448/rsd-v11i1.24445Research, Society and Development; Vol. 11 No. 1; e11611124445Research, Society and Development; Vol. 11 Núm. 1; e11611124445Research, Society and Development; v. 11 n. 1; e116111244452525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/24445/21685Copyright (c) 2022 Tatiana Aparecida Furuzawa; Gabriel Fernando Esteves Cardia; Mariana Vessoni Iwaki; Edivaldo Cremer; Ricardo Alexandre Spironello; Francielli Maria de Souza Silva Comar; Roberto Kenji Nakamura Cumanhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFuruzawa, Tatiana Aparecida Cardia, Gabriel Fernando Esteves Iwaki, Mariana Vessoni Cremer, EdivaldoSpironello, Ricardo Alexandre Comar, Francielli Maria de Souza Silva Cuman, Roberto Kenji Nakamura 2022-01-16T18:08:18Zoai:ojs.pkp.sfu.ca:article/24445Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:42:59.854477Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 Estudio de fármacos seleccionados en ensayos clínicos en la terapia farmacológica de la COVID-19 Estudo dos fármacos selecionados em ensaios clínicos na terapia farmacológica da COVID-19 |
title |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 |
spellingShingle |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 Furuzawa, Tatiana Aparecida COVID-19 SARS-CoV-2 Medicamentos Ensayos Clínicos Terapéutica. COVID-19 SARS-CoV-2 Medicamentos Ensaio Clínico Terapêutica. COVID-19 SARS-CoV-2 Drugs Trials Clinicals Therapeutics. |
title_short |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 |
title_full |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 |
title_fullStr |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 |
title_full_unstemmed |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 |
title_sort |
Study of selected drugs in clinical trials in the pharmacological therapy of COVID-19 |
author |
Furuzawa, Tatiana Aparecida |
author_facet |
Furuzawa, Tatiana Aparecida Cardia, Gabriel Fernando Esteves Iwaki, Mariana Vessoni Cremer, Edivaldo Spironello, Ricardo Alexandre Comar, Francielli Maria de Souza Silva Cuman, Roberto Kenji Nakamura |
author_role |
author |
author2 |
Cardia, Gabriel Fernando Esteves Iwaki, Mariana Vessoni Cremer, Edivaldo Spironello, Ricardo Alexandre Comar, Francielli Maria de Souza Silva Cuman, Roberto Kenji Nakamura |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Furuzawa, Tatiana Aparecida Cardia, Gabriel Fernando Esteves Iwaki, Mariana Vessoni Cremer, Edivaldo Spironello, Ricardo Alexandre Comar, Francielli Maria de Souza Silva Cuman, Roberto Kenji Nakamura |
dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Medicamentos Ensayos Clínicos Terapéutica. COVID-19 SARS-CoV-2 Medicamentos Ensaio Clínico Terapêutica. COVID-19 SARS-CoV-2 Drugs Trials Clinicals Therapeutics. |
topic |
COVID-19 SARS-CoV-2 Medicamentos Ensayos Clínicos Terapéutica. COVID-19 SARS-CoV-2 Medicamentos Ensaio Clínico Terapêutica. COVID-19 SARS-CoV-2 Drugs Trials Clinicals Therapeutics. |
description |
COVID-19 is an acute respiratory infection caused by the potentially severe, highly transmissible, globally distributed SARS-CoV-2 coronavirus. The search for drugs that have activity on SARS-CoV-2 is a constant challenge without precedent in the validation of effective drugs in the treatment of patients affected by COVID-19. Objective: This integrative review aimed to assess studies in the scientific literature, involving clinical trials that evaluate the efficacy of drugs already available on the market for probable use in the treatment of COVID-19. Methodology: The search was conducted from April 2020 to June 2021 in the PubMed, SciElo and Lilacs databases, using the Health Science Descriptors (DeCS) "COVID-19", "SARS-CoV-2", "Drugs", "Trials Clinicals", "Treatments". The criteria for inclusion of articles in the search were those with abstract and text available in full electronically, written in English, Portuguese, and Spanish, published from April 2020 to June 2021, in scientific journals, and that evaluated the efficacy of probable drugs in the treatment of COVID-19 and clinical trials in hospitalized patients with the disease. Articles that did not jointly address the topic of the study, duplicate articles in the databases, review articles, articles based on in vitro / in vivo animal trials, articles based on traditional medicine, editorial type studies and also the reflexive articles were excluded. Results: Of the 210 articles identified, 132 were excluded for not meeting the inclusion criteria, and 78 articles that aimed to study drug efficacy in international clinical trials were selected for this study. Of these, 67 were in PubMed, 6 in SciELO, and 5 in Lilacs. A total of 49 drugs were analyzed, classified into 22 pharmacological classes. The main classes of drugs in studies were: direct acting antivirals in monotherapy, 8 (16.32%); immunomodulators, 7 (14.28%); immunomodulators + associations, 2 (4.08%); and immunostimulants + associations, 2 (4.08%). Conclusion: The drugs and their associations under study did not show specific therapeutic efficacy for the treatment of COVID-19; however, clinical trials indicated improvement in patients' clinical symptoms and hospital length of stay. However, some drugs showed significant adverse reactions, directly interfering with patient safety. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-03 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/24445 10.33448/rsd-v11i1.24445 |
url |
https://rsdjournal.org/index.php/rsd/article/view/24445 |
identifier_str_mv |
10.33448/rsd-v11i1.24445 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/24445/21685 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 1; e11611124445 Research, Society and Development; Vol. 11 Núm. 1; e11611124445 Research, Society and Development; v. 11 n. 1; e11611124445 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052826079199232 |